AstraZeneca has announced a delay to the beginning of its Phase III programme - the last stage of development- for CytoFab, a treatment for severe sepsis that it has licensed from Protherics.
Phase III is now expected to begin in late 2009.
The news comes a week after the drug company said it had abandoned its Cerovive stroke treatment.
No comments:
Post a Comment